Article Text

Download PDFPDF

1196 GDF-15 neutralizing antibody visugromab increases intratumoral immune cell infiltration to support bispecific T-cell engagers
  1. Sabrina Genssler,
  2. Daniel Schaetzlein,
  3. Eugen Leo,
  4. Markus Haake and
  5. Christine Schuberth-Wagner
  1. CataYm GmH, Planegg-Martinsried, Germany


Background GDF-15, a member of the TGF-beta superfamily, is a critical factor of feto-maternal tolerance, but also of local immune suppression at sites of cellular stress. Various solid tumor types secrete high levels of this immunosuppressive cytokine. In cancer patients, elevated GDF-15 serum levels correlate with poor prognosis and reduced overall survival.1 Mechanistically GDF-15 interferes with LFA-1/ICAM-1 dependent immune cell extravasation and thus limits immune infiltration into GDF-15 expressing tumors. In line with immune infiltration as a prerequisite of checkpoint-inhibitor responses GDF-15 serum levels negatively correlate with the response to anti-PD-(L)1 CPI therapy.2 3 Neutralization by clinical stage GDF-15 neutralizing antibody visugromab (CTL-002; GDFather-1/2 trial NCT04725474) restores responsiveness to anti-P(L)1 by increasing extravasation of immune cells into the tumor microenvironment.2 To be active, bispecific T-cell engagers are dependent on infiltration of T-cells into the tumor tissue. Once bound to both T-cell and tumor cell, bispecifics retain T-cells at cancer cell sites. In this study we tested the synergy of visugromab with tebentafusp, a CD3-cell redirecting bispecific fusion protein for gp100+ tumors, to enhance effector T-cell retention in the tumor.

Methods Specific binding and cytotoxic activity of tebentafusp was qualified by flow-cytometry and cytotoxicity assays with HLA-A2+ gp100+ human SK-MEL-5-melanoma cells, respectively. In vivo T-cell retention was tested in PBMC-humanized NOG mice, treated with tebentafusp4 and isotype or a combination of tebentafusp and visugromab. After five days body weight, serum GDF-15, tumor size/weight and mouse and human immune cell infiltration were measured as a final read-out.

Results Tebentafusp bound gp100 on GDF-15 secreting HLA-A2+ SK-MEL-5 melanoma cells and mediated tumor specific killing by T cells in vitro. In vivo, treatment with tebentafusp in combination with isotype resulted in a 4.3-fold increase in T-cell numbers in s.c. SK-MEL-5 tumors in PBMC-humanized NOG mice, while in combination with visugromab, a 15.3-fold increase was observed.

Conclusions GDF-15 is an inhibitor of immune infiltration, and its neutralization enhances effector cell presence in tumors. Bispecific T-cell engagers are dependent on proper effector cell infiltration into tumors to induce significant tumor cell killing. In a PD study combining tebentafusp with anti-GDF-15 antibody visugromab significantly increased the number of intratumoral T cells in mice. Increasing the number of effector cells in the tumor microenvironment is expected to have a direct positive impact on the anti-tumor activity of different bispecific T-cell engaging treatments.


  1. Wischhusen J, et al. Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front Immunol. 2020 May 19;11:951. PubMed PMID: 32508832

  2. Haake M, et al. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment. Nat Commun. 2023, in press

  3. Hong G, et al. Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2023 Jan;149(1):159–171. PubMed PMID: 36472770

  4. Chen LN, Carvajal RD. Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Expert Rev Anticancer Ther. 2022 Oct;22(10):1017–1027. PubMed PMID: 36102132

Ethics Approval This study was approved by EPO Berlin’s Ethics Board; approval number E0023–23.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.